Dr Manfred Ruediger was formerly CEO of Kiadis Pharma, developing a cell therapy for blood cancer patients, and led the company to a successful IPO on Euronext Amsterdam and Brussels in 2015. He also advanced the company’s programs towards late-stage clinical development and pre-commercialization stages including submission-readiness for marketing authorization of its lead product ATI101. Prior to joining Kiadis, he was Chief Scientific Officer and acting CEO of Cardion AG, CEO of Igeneon AG, Chief Operating Officer of NASDAQ-listed Aphton Corporation, and lastly CEO of t2cure GmbH and Affectis AG. He is a member of the Supervisory Board of 4SC AG as well as a member of the Investment Committee and Advisory Board of ALS Investment Fund and a member of the Scientific Advisory Board of Medigene AG. Dr Ruediger holds a PhD in Biochemistry from the Max-Planck-Institute for Biophysical Chemistry in Göttingen, Germany, and worked at the Technical University of Braunschweig, Germany, before he joined the industry.


Dr Klaus Schollmeier has more than 30 years’ experience as a senior executive and advisor to the pharmaceutical and biotech industry, as well as in investment banking. Dr Schollmeier is currently CEO of KCS-GmbH, a consulting and investment company, and serves as non-executive chairman of several European Biotechnology companies. He was formerly CEO of SuppreMol GmbH, which was acquired by Baxter in 2015 for € 220 Mio. Before that, he led Santhera Pharmaceuticals AG as CEO since the company’s foundation in 2004, took the company public in 2006 and launched the first product in 2008. Prior to that, Dr. Schollmeier spent 16 years in the pharmaceutical industry at BASF, Knoll and Abbott. His scientific responsibilities included head of oncology/immunology research at BASF’s central laboratories in Germany, and senior director of biotechnology at BASF Bioresearch Corporation in Cambridge, US. His business functions included General Manager of BASF Pharma Netherlands and Vice President and General Manager for Western Europe. Dr Schollmeier holds a Ph.D. in Biology from the University of Düsseldorf, Germany.


Dr Matthias Kromayer is a General Partner and member of the Executive Board of MIG Verwaltungs AG, responsible for the MIG Funds’ holdings in the life sciences. He is also Member of the Supervisory Boards of Biocrates AG, Immatics Biotechnologies GmbH and Amsilk GmbH. After working for several years as a management consultant and in corporate development at Xerion Pharmaceuticals AG, Dr Kromayer founded tavia consulting, a strategic consulting company specialized in the life sciences sector and advised more than 30 companies on their business strategy. In addition, he has extensive entrepreneurial experience building and running companies. Dr Kromayer received training at King’s College London, UK, and Lund University, Sweden, and holds a diploma in biology and a doctorate in molecular biology from the University of Munich. He is an alumnus and member of the selection committee of the Studienstiftung des Deutschen Volkes.


Professor Dr Hans-Jochem Kolb is a highly recognized specialist in hematological oncology, particularly known as a scientific and clinical pioneer of cellular immunotherapy and bone marrow/stem cell transplantation in Germany. He received his Medical Degree at the Universities of Freiburg, Innsbruck, Vienna and Munich, and worked as a postdoctoral researcher with the later Nobel laureate Edward Donnall Thomas and Rainer Storb at the University of Washington in Seattle. Professor Kolb performed the first successful bone marrow transplantation to a patient in Germany. He was formerly Head of the Clinical Cooperative Group Haematopoietic Cell Transplantation University of Munich (LMU) & GSF. While he recently retired as a Professor of Medicine and a senior physician at the LMU, he remains a visiting professor and consultant at various universities in the USA, Brazil and Germany. Professor Kolb has won several prestigious awards, including the Mortimer M. Bortin Award, Jakob Henle Preis, and Preis der Deutschen Krebshilfe, for his medical and scientific contributions.